Impact of AML1/ETO Fusion on the Efficacy of Venetoclax Plus Hypomethylating Agents in Newly Diagnosed Acute Myeloid Leukemia.
Dian JinHaoguang ChenJingsong HeYi LiGaofeng ZhengYang YangYi ZhaoJing LeWenxiu ShuDonghua HeZhen CaiPublished in: Targeted oncology (2024)
Newly diagnosed AML patients with AML1/ETO fusion had a poor response to frontline VEN/HMA treatment. When determining induction therapy for patients with AML1/ETO-positive AML, IC should be preferred over VEN/HM.